Inhibikase Therapeutics, Inc.’s IKT share price has dipped by 13.59%, which has investors questioning if this is right time ...

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial HypertensionBOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc.

Every investor in Inhibikase Therapeutics, Inc. (NASDAQ:IKT) should be aware of the most powerful shareholder groups. We can see that hedge funds own the lion's share in the company with 31% ownership ...

H.C. Wainwright analyst Edward White reiterated a Hold rating on Inhibikase Therapeutics (IKT – Research Report) today. The company’s shares ...

IKT stock opened at $2.29 on Friday. The stock’s 50 day moving average price is $2.42 and its 200 day moving average price is $2.38. The firm has a market cap of $158.84 million, a P/E ratio of ...

BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company ...

At 90 days, participants randomized to the Felix NeuroAI transcutaneous peripheral nerve stimulation (TPNS) system showed ...

New Leadership and Focus on Advancement of IkT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension BOSTON, March 27, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. ...